Effect of intravenous metoclopramide on gastrooesophageal reflux

J. N. GLANVILLE AND W. D. WALLS

From the Departments of Diagnostic Radiology and Medicine, Chapel Allerton Hospital, Leeds

SUMMARY The effect of intravenous metoclopramide was studied radiologically in 40 patients with gastrooesophageal reflux. In no patient was reflux significantly diminished.

Metoclopramide activates gastrointestinal motility. It accelerates gastric emptying (Jacoby and Brodie, 1967; Connell and George, 1969; Kree, 1970; Howels, Khanam, Kree, Seymour, Oliver, and Davies, 1971) and stimulates contraction of the small bowel (Tinker and Cox, 1969). These effects may be due to activation of intramural cholinergic motor mechanisms (Jacoby and Brodie, 1967; Eiser, 1968). It is widely used as an antiemetic and is useful in controlling the symptoms of flatulent dyspepsia, including heartburn (Johnson, 1971).

In 1970 Heitmann and Müller (1970) reported that intravenous infusion of metoclopramide into normal subjects significantly increased gastrooesophageal sphincteric pressure and also the strength and duration of peristaltic waves in the lower oesophagus. Neither relaxation of the sphincter in response to swallowing nor the normal reflex rise in sphincter pressure resulting from an increase in intraabdominal pressure were impaired. Thus in patients with oesophageal reflux, metoclopramide may increase gastrooesophageal sphincter pressure to levels exceeding intraabdominal pressure and thereby prevent reflux. We have investigated this possibility radiologically.

Patients

Three groups were investigated.

GROUP 1
Twenty patients with radiologically demonstrable hiatus hernia and gastrooesophageal reflux.

GROUP 2
Twenty patients with radiologically demonstrable gastrooesophageal reflux but without hiatus hernia.

GROUP 3
Fifteen patients with symptoms suggestive of gastro-

Received for publication 2 November 1971.

Gut, 1972, 13, 31-32
sionally, we gained an impression that reflux increased slightly following metoclopramide in groups 1 and 2. This led to the investigation of patients in group 3 but none developed reflux after receiving metoclopramide.

Discussion

These results are disappointing in view of the encouraging increase in pressure at the gastrooesophageal sphincter reported by Heitmann and Möller (1970). They, of course, were dealing with healthy subjects with presumably normal sphincters in contrast to our groups 1 and 2. It was also noted, however, that even in normal subjects, the lower the initial sphincter pressure the less was the increase in response to metoclopramide. Thus as patients with reflux have lower sphincter pressures than subjects without reflux (Cohen and Harris, 1971) the lack of response of groups 1 and 2 might be expected.

An alternative, but unlikely, explanation for the apparent discrepancy between our results and those of Heitmann and Möller (1970) is that they gave metoclopramide by intravenous infusion at 0.4 mg/min for 50 min recording pressure changes 10 min after starting the infusion, whereas we gave 10 mg as an intravenous bolus reassessing the degree of reflux at five and 10 minutes.

It is concluded that under the conditions of this investigation metoclopramide did not diminish oesophageal reflux and therefore is unlikely to benefit patients with reflux oesophagitis. However, the possibility that a more prolonged course of oral metoclopramide may be more effective than a single intravenous dose is about to be investigated.

References


Effect of intravenous metoclopramide on gastrooesophageal reflux

J. N. Glanville and W. D. Walls

Gut 1972 13: 31-32
doi: 10.1136/gut.13.1.31

Updated information and services can be found at:
http://gut.bmj.com/content/13/1/31

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/